Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580030 | 1.00 | APLNR (0.75) | APLNRHTR2AHTR2CPDCD1CD274 | |
| SCHEMBL2883792 | 0.91 | APLNR (0.71) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL7768853 | 0.90 | APLNR (0.86) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL20558263 | 0.89 | APLNR (0.69) | APLNRHTR2AHTR2CTSHR | |
| SCHEMBL2551631 | 0.88 | APLNR (0.67) | APLNRHTR2AHTR2CTSHR | |
| SCHEMBL28318209 | 0.87 | APLNR (0.80) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL783785 | 0.86 | APLNR (1.00) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL18256578 | 0.85 | APLNR (0.77) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL31114343 | 0.84 | APLNR (0.75) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL7002432 | 0.83 | APLNR (0.73) | APLNRHTR2AHTR2CHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472734-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021147986-A1 | CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | 上海森辉医药有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3559007-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-30 | — | — | EP | disclosed |
| CN-107207527-B | Pyridooxazinone compounds as TNAP inhibitors | 第一三共株式会社 | 2019-10-01 | — | — | CN | disclosed |
| US-9920068-B2 | Pyridine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9879032-B2 | Pyridine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| CN-107207527-A | Pyridooxazinone compounds as TNAP inhibitors | 第三共株式会社 | 2017-09-26 | — | — | CN | disclosed |
| US-20170240562-A1 | PYRIDINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170210755-A1 | PYRIDINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9676736-B2 | 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| EP-2837624-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| CN-102675240-B | 4-substitute-2-hydroxy morpholine-3-ketone and preparation method thereof | ZHEJIANG HISUN PHARM CO LTD | 2015-01-14 | — | — | CN | disclosed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240562-A1 | PYRIDINE COMPOUNDS | ALPI, ALPP, ALPL | APLNR 1140/4885HTR2A 4352/4885HTR2C 3454/4885 |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | APLNR 1514/4885HTR2A 4268/4885HTR2C 4110/4885 |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | OPRK1, HTR3C, HTR3A | APLNR 319/4885HTR2A 32/4885HTR2C 14/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | APLNR 593/4885HTR2A 4122/4885HTR2C 3688/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | APLNR 1514/4885HTR2A 4268/4885HTR2C 4110/4885 |
| US-20170210755-A1 | PYRIDINE COMPOUNDS | ALPI, ALPP, ALPL | APLNR 1140/4885HTR2A 4352/4885HTR2C 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.